ASX Announcements

Dec 2017
Dec 21st, 2017
VivaGel® BV treatment clinical submission under rolling submission
Dec 11th, 2017
Change in Director's Interest Notice - J Fairley
Dec 11th, 2017
Appendix 3B
Dec 5th, 2017
Change in Director's Interest Notice - R Thomas

Nov 2017
Nov 29th, 2017
AGM Chairman's address and CEO presentation
Nov 29th, 2017
AGM Results
Nov 29th, 2017
Starpharma's amended Constitution
Nov 21st, 2017
NDA submission for VivaGel BV in the US
Nov 8th, 2017
Change in Director's Interest Notice - J Fairley

Oct 2017
Oct 31st, 2017
Change in Director's Interest Notice - R Thomas
Oct 27th, 2017
Notice of Annual General Meeting/Proxy Form
Oct 26th, 2017
Appendix 4C - Quarterly Cashflow Report
Oct 25th, 2017
VivaGel® BV granted marketing approval in Australia
Oct 18th, 2017
Shareholder Update October 2017
Oct 12th, 2017
Appendix 3B
Oct 9th, 2017
Starpharma and Peter Mac Cancer Centre awarded DEP® Grant
Oct 5th, 2017
Change in Director's Interest Notice - J Fairley
Oct 5th, 2017
Appendix 3B
Oct 2nd, 2017
Notification of AGM date

Sep 2017
Sep 28th, 2017
AstraZeneca presents first DEP® candidate as Bcl2-xL inhibitor
Sep 22nd, 2017
DEP® docetaxel positive phase 1 results; phase 2 commences

Aug 2017
Aug 28th, 2017
Annual report and full year financial results
Aug 28th, 2017
Appendix 4G - Corporate Governance Statement
Aug 24th, 2017
Starpharma to present at Finance News Network Investor Event
Aug 21st, 2017
Appendix 3B
Aug 9th, 2017
Starpharma and Monash awarded STEM+ Business Fellowships
Aug 7th, 2017
Successful VivaGel Phase 3 results and NDA planned for rBV

Jul 2017
Jul 19th, 2017
Appendix 4C - Quarterly Cashflow Report
Jul 4th, 2017
VivaGel® BV phase 3 results timing and commercialisation
Jul 4th, 2017
Shareholder Update July 2017

Jun 2017
Jun 14th, 2017
Starpharma sells Agrochemicals business to Agrium for $35M
Jun 14th, 2017
Sale of Agrochemicals Business Investor Presentation
Jun 14th, 2017
Appendix 3B
Jun 6th, 2017
DEP® irinotecan outperforms irinotecan in multiple cancer models
Jun 2nd, 2017
Starpharma receives DEP® milestone from AstraZeneca

Apr 2017
Apr 28th, 2017
Appendix 4C - Quarterly Cashflow Report
Apr 20th, 2017
AstraZeneca DEP® candidate advance triggers milestone to Starpharma
Apr 12th, 2017
Ansell launches VivaGel® condom in Canada

Mar 2017
Mar 30th, 2017
VivaGel® BV phase 3 trials for prevention of BV completed

Feb 2017
Feb 27th, 2017
Interim Report and Half-Yearly Financial Results

Jan 2017
Jan 31st, 2017
Appendix 4C - Quarterly Cashflow Report
Jan 25th, 2017
Appendix 3B
Jan 19th, 2017
Shareholder Update January 2017
Jan 12th, 2017
VivaGel® BV granted QIDP and Fast Track designation by US FDA